What is ATRC's 12-month stock price target?

AtriCure Inc. (ATRC) carries a 12-month consensus base price target of $61.23 (+2.3% from $59.88), with a bull-case target of $72.25 and a bear-case floor of $47.76.

Stock Ratings / Health Care / ATRC / forecast

PLSE (39) NVST (46) IRTC (47) ICUI (56) ⌘ Pro Terminal →

AtriCure Inc. (ATRC) 12-Month Stock Forecast & Price Target Cone

Q: Is ATRC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ATRC C (Hold — HOLD) with an RQD Confidence score of 63/100.

$59.88 -2.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.52

AtriCure Inc. (ATRC) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $3.12B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATRC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, AtriCure Inc. (NASDAQ: ATRC) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $59.88 (-2.24% 1D, market cap $3.12B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, ATRC ranks #138 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATRC compare to PLSE and NVST in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), ATRC carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 75.0%, and ROIC of -1.9%. By comparison, PLSE (Pulse Biosciences Inc) holds a D- grade (39/100 RQD, P/E N/A, ROIC -30.7%, cap $3.73B) and NVST (Envista Holdings Corporation) posts a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATRC?

▼

Per ATRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001323885), AtriCure Inc. generated $534.5M in revenue (+14.9% YoY), -$11.4M in net income, and $48.3M in free cash flow against $654.2M in total assets and $61.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $59.53 (-0.59%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATRC)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY ATRC SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (27% of score)

20D Institutional Volume Accumulation (±7.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 12.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$56.87+1.4% Next Q

Q2 (-2Q)

Grade C$57.67+6.7% Next Q

Q3 (-1Q)

Grade C$61.51-2.6% Next Q

Current

Grade C$59.88+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ATRC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, ATRC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 72.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($56.09) or 200D SMA ($38.30) invalidates the momentum regime and cuts Target Base ($61.23) toward Bear Floor ($47.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATRC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ATRC Position Size: $10,000

Shares at $59.88: 167.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $47.76

$7,976

$-2,024 (-20.2%)

12M Consensus BaseTarget $61.23

$10,225

+$225 (+2.3%)

12M Bull Case BreakoutTarget $72.25

$12,066

+$2,066 (+20.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$64	74%	A
Goldman SachsSector Coverage Lead	BUY	$68	69%	B
JP MorganUS Large-Cap Research	HOLD	$54	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ATRC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +108.06%🛡️ HOLDING TREND SUPPORT

2026-11-03O $62.48H $62.48L $59.88C $59.88VOL 967.4K

RES: $71.85SUP: $58.21SMA50: $56.09SMA200: $38.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATRC Butterfly Map → + Track ATRC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATRC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATRC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATRC)

Health Care Rank #138 of 1015 ⚔️ PLSE vs ATRC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATRC vs. PLSE, NVST, IRTC, ICUI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AtriCure Inc. (ATRC) ranks #138 by composite RQD confidence (63/100, grade C) and #200 by equity capitalization ($3.12B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATRC ACTIVE AtriCure Inc.	C	63/100	—	75.0%	-1.9%	-2.24%	$3.12B	Benchmark Subject
PLSE Pulse Biosciences Inc	D-	39/100	—	-30.0%	-30.7%	+1.26%	$3.73B	/plse-vs-atrc →
NVST Envista Holdings Corporation	D	46/100	84.1x	54.7%	5.1%	+5.10%	$3.78B	/nvst-vs-atrc →
IRTC iRhythm Holdings Inc.	D	47/100	—	70.6%	-13.5%	+2.27%	$4.07B	/irtc-vs-atrc →
ICUI ICU Medical Inc.	D+	56/100	—	36.8%	1.0%	-0.85%	$4.10B	/icui-vs-atrc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001323885 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AtriCure Inc. (ATRC) reported GAAP revenue of $534.5M (+14.9% vs. FY2024 revenue of $465.3M , and +33.9% cumulative change since FY2023) , GAAP net income of -$11.4M, operating cash flow of $57.3M, and free cash flow of $48.3M (+6381.1% YoY). On the balance sheet, ATRC closed FY2025 with $654.2M in total assets against $61.9M in total debt (Altman Z-Score: 12.08, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$534.5M	-$11.4M	$57.3M	$48.3M	$654.2M	$61.9M
FY2024 (FY)	2024-12-31	$465.3M	-$44.7M	$12.2M	$745.0K	$609.3M	$61.9M
FY2023 (FY)	2023-12-31	$399.2M	-$30.4M	$4.5M	$4.5M	—	—

3. ATRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATRC compare to PLSE and NVST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATRC?

Where is ATRC trading relative to its 50-day, 200-day, and 52-week technical levels?

ATRC last traded at $59.88 (-2.24% on volume of 1,122,979 shares), positioning the stock +6.76% above its 50-day simple moving average ($56.09) and +56.34% above its 200-day simple moving average ($38.30). Across its 52-week range of $25.36 to $63.00, ATRC sits at the 91.7% percentile with a 14-day RSI of 60.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.3% ($55.51 to $64.25).

Direct Sub-Reports: ATRC RQD Cockpit ATRC 12M Forecast ATRC Earnings & Move ATRC Dividends & DRIP ATRC Insiders & 13F ATRC Whale Options ATRC Profit Sankey ATRC News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

ATRC — AtriCure Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AtriCure Inc. (ATRC) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $59.88 (-2.24% 1D, market capitalization $3.12B).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -1.9%, gross margin of 75.0%, operating margin of -1.8%, and free cash flow yield of 1.52%.
Whale 13F & Options Flow (17/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 12.08, Piotroski F-Score of 8/9, and Debt/Equity of 0.13x.

2. Business Model, Unit Margins & SEC Financial Trajectory

AtriCure Inc. (ATRC) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. It has a market capitalization of $3.2B. The company reported revenue of $534.5M for FY 2025, indicating an operating business of meaningful scale.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AtriCure Inc. (ATRC) reported $534.5M in annual revenue (up from $465.3M in FY2024, +14.9% YoY) and -$11.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($399.2M revenue, -$30.4M net income) through FY2025, ATRC scaled operating cash flow to $57.3M and free cash flow to $48.3M, backed by $654.2M in total assets against $61.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 63/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $25.36 – $63.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -1.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector classification is Health Care, Medical/Dental Instruments.

Key Question #1: Can ATRC sustain or expand its -1.8% operating margin and -1.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $534.5M and free cash flow of $48.3M, how will capital allocation balance growth reinvestment against $61.9M in total debt?
Key Question #3: How sensitive is ATRC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATRC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AtriCure Inc. (ATRC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATRC Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks

Yahoo Finance report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

AtriCure Inc (ATRC) Shares Surge 3.9% -- What GF Score of 74 Tel

GuruFocus report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

AtriCure (ATRC) Stock Looks Overvalued Based On Its Sales

Simply Wall St report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

AtriCure, Inc. (ATRC) Stock Forecasts

Yahoo Finance report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

AtriCure (ATRC) Gains 2.40% to $59.05 as Medical Device Stock Tests Resistance - OBV Trend Line

https://www.siam.in/ report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 1d ago

Citizens raises AtriCure target to USD 68 for AtriCure stock

ad-hoc-news.de report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

AtriCure (ATRC) Jumps 75% In 90 Days, Is The Stock Now Too Expensive?

Simply Wall St report covering AtriCure Inc. (ATRC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE SeekingAlpha • 6d ago

Riverwater Small Cap Strategy Q3 2026 Portfolio Update

Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. Read more here.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATRC Bull vs. Bear Conversation Board — What's Your Call at $59.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATRC 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $79.62 (+30.0%)

📌 Pinned Debate

A 12.08 Altman Z-Score, 8/9 Piotroski F-Score, and 0.13 Debt/Equity point to a low-leverage balance sheet with $167.4M in FY 2025 cash.

Here is why I am bullish on ATRC here at $61.25: A 12.08 Altman Z-Score, 8/9 Piotroski F-Score, and 0.13 Debt/Equity point to a low-leverage balance sheet with $167.4M in FY 2025 cash.. Compare ATRC's -1.8% operating margin and -1.9% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $58.19 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — ATRC's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $47.16 (-23.0%)

Spot @ $61.25

Operating margin of -1.8% and ROIC of -1.9% show the business is not yet earning returns on invested capital despite a $3.18B market ca

Careful chasing ATRC at $61.25. Operating margin of -1.8% and ROIC of -1.9% show the business is not yet earning returns on invested capital despite a $3.18B market cap.. Gross margin is 75.0%, but operating margin is -1.8%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $47.16 on multiple compression.